Companies › Veru
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Oct 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Enobosarm Androgen Receptor modulator | AR | Phase 2 | Obesity & Overweight | Oct 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07446998 | Enobosarm | Phase 2 | Obesity & Overweight | Metabolic and endocrine | Oct 2027 |
Cash of $24m on 2026-06-30; operating cash outflow about $28m a year; runway about 10 months at that burn, to May 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Skye Bioscience Actimed Therapeutics PolTREG Protalix Verdiva Bio Dev
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.